DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/26/19

Ripretinib is Deciphera's ( DCPH ) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST. Given those result...

Accomplished Former COO of Deloitte Brings Extensive Strategic, Operational and Business Expertise Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank ...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

- Preliminary Anti-tumor Activity Observed in Initial Diffuse-type TGCT Patients Treated with DCC-3014 in Ongoing Phase 1 Study - - DCC-3014 was Generally Well Tolerated with No Reported Grade 3 or Higher TEAEs in Initial Diffuse-Type TGCT Patients - - Encore Presentation of Resul...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that members of the management team will present at the following investor conferences: Jefferies 2019 London Healthca...

Blueprint suffers GIST setbacks NDA changes Blueprint Medicines ( BPMC ) recently announced the FDA will split Avapritinib New Drug Application into separate submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST, setting the company back a quarter. In order to prioritize ...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 ET Company Participants Jennifer Robinson - VP, Investor Relations Steven Hoerter - President, CEO & Director Matthew Sherman - Chief Medical Officer Tucker Kelly - CFO & Tr...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc.   (NASDAQ: DCPH) Q3 2019 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q3 GAAP EPS of -$1.28 misses by $0.12 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...